An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

An Omnicom spokesperson confirmed that the 2025 MM+M Agency 100 honoree will soon be folded into Omnicom Health subsidiaries.

European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

This month in the Zantac litigation, the Delaware Supreme Court tossed all the plaintiffs’ experts in thousands of cases, ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

U.S. stocks appear poised for a positive opening on Friday, as strong earnings from major companies throughout the week have ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...